JP2009215251A - Anti-inflammatory agent and skin care preparation for anti-inflammation use - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a new anti-inflammatory agent having high safety and a skin care preparation for anti-inflammation use. <P>SOLUTION: Provided are an anti-inflammatory agent containing the extract of Blechnum discolor belonging to the genus Blechnum, family Blechnaceae and order Filicales as an active component, and a skin care preparation for anti-inflammation use containing the anti-inflammatory agent. The anti-inflammatory agent has degranulation suppressing activity accompanying the isolation of β-hexosaminidase and, accordingly, is useful for suppressing or ameliorating inflammation caused by a pharmacologically active substance such as histamine included in the released granules. <P>COPYRIGHT: (C)2009,JPO&INPIT

Description

  The present invention relates to a novel anti-inflammatory agent and anti-inflammatory skin external preparation.

Conventionally, plant-derived components have been used in various ways as medicinal components for external preparations for skin, foods, medicines and the like because of their good safety. Various uses for external preparations for skin have also been proposed for extracts obtained from the genus Lechnaceae (Blechnum) Brechnum discolor (Patent Documents 1 to 4).
However, none of the above patent documents describes the anti-inflammatory action of the extract.
Japanese Patent Laying-Open No. 2005-232131 JP 2003-321377 A JP 2003-095910 A JP 2002-020232 A

  An object of the present invention is to provide a novel anti-inflammatory agent and an anti-inflammatory skin external preparation with good safety.

In order to solve the above-mentioned problems, the present invention contains an anti-inflammatory agent containing, as an active ingredient, an extract of a Lepidoptera (Blechnaceae) genus Blechnum (Blechnum) discolor (Blechnum discoror) and an active ingredient thereof. An anti-inflammatory skin external preparation is provided.
The anti-inflammatory agent of the present invention has the ability to inhibit β-hexosaminidase release.
Further, the anti-inflammatory agent of the present invention has an ability to suppress degranulation accompanied by the release of β-hexosaminidase.

  ADVANTAGE OF THE INVENTION According to this invention, the safe anti-inflammatory agent derived from a plant and the anti-inflammatory skin external preparation can be provided. Since the anti-inflammatory agent of the present invention has the ability to suppress degranulation accompanied by the release of β-hexosaminidase, it can suppress or improve inflammation caused by pharmacologically active substances such as histamine contained in the released granules. Useful.

Hereinafter, the present invention will be described in detail. In the present specification, “to” means a range including numerical values before and after.
The present invention is an anti-inflammatory comprising an extract of a New Zealand native Brechnaceae Blechnum discolor (hereinafter sometimes referred to as a “Brechnum discolor extract”) as an active ingredient. It relates to the agent. The Bleknum discolor extract used in the present invention can be prepared by a general method. There is no particular limitation on the extraction site, and it may be an extract of any part of the fern plant, such as root, stem, stem, leaf, spore, etc., and an extract obtained from two or more parts is mixed. Or two or more extracts extracted from two or more portions with different solvents may be used.

The Bleknum discolor extract can be obtained by extracting one or two or more sites such as roots, stems, stems, leaves or spores of a bleknum discolor with a suitable solvent. These portions may be appropriately subjected to a treatment such as drying, shredding, pressing or fermentation, followed by an extraction treatment. The extraction can be performed by immersing the fern plant in a solvent at a low temperature or under a predetermined time for a predetermined time.
Although it does not specifically limit as an extraction solvent, For example, Water; Lower monohydric alcohols, such as methyl alcohol and ethyl alcohol; Liquid polyhydric alcohols, such as glycerol, propylene glycol, and 1, 3- butylene glycol; Ketones, such as acetone; Ethyl One or more of ethers such as ether; esters such as ethyl acetate; and the like can be used. It is preferable to use a mixed solution of water and a lower alcohol.

  The Bleknum discolor extract can be used as an anti-inflammatory agent as it is. In addition, if desired, the composition can be used as an anti-inflammatory agent after being left to mature for an appropriate period. If necessary, it can be used after being subjected to a purification treatment such as deodorization and decolorization by filtration or ion exchange resin within a range that does not affect the effect of the present invention. Further, a fraction having high activity can be taken out and used by using a separation means such as liquid chromatography.

  As an example of a preferable method for preparing the Bleknum discolor extract, water-containing ethyl alcohol or 1,3-butylene glycol having a concentration of 0 to 100 vol% was used, and extraction was performed at room temperature or with heating for 1 to 5 days. Thereafter, filtration is performed, and the obtained filtrate is further left to mature for about one week, followed by filtration again. However, the extraction method is not limited to this.

  The Bleknum discolor extract may be in any form such as liquid, paste or gel. The liquid extract containing the extraction solvent can also be used after it is solidified by drying under reduced pressure or freeze drying. It can also be dried by spray drying or the like and used as a powder.

  Several mechanisms have been elucidated for the mechanism of inflammation. As one of them, it is known that degranulation in which granules containing physiologically active substances such as histamine are released from cells by antigen stimulation is involved. The anti-inflammatory agent of this invention has the effect of suppressing or improving inflammation by suppressing this degranulation. Although it is difficult to directly confirm this ability to suppress degranulation, the present inventors have shown that the anti-inflammatory agent of the present invention is released by β-hexosaminidase during degranulation according to Examples described later. It was confirmed that the anti-inflammatory agent of the present invention has a degranulation inhibitory ability and has an inhibitory or ameliorating effect on inflammation caused by degranulation.

  The present invention also relates to an external preparation for skin containing as an active ingredient the anti-inflammatory agent of the present invention, that is, the Bleknum discolor extract. Since the external preparation for skin of the present invention exhibits a high anti-inflammatory effect by the above-mentioned Bleknum discolor extract, it is useful as an anti-inflammatory external preparation for skin that exhibits an action of suppressing or improving inflammation of the skin when applied to the skin. is there. The content of the Bleknum discolor extract (dry solid) in the external preparation for skin of the present invention is preferably 0.00001 to 5% by mass (hereinafter simply referred to as “%”), more preferably 0.001. ~ 0.5%. Within this range, the Bleknum discolor extract can be stably blended and can exhibit a high anti-inflammatory effect. When the extract is used as a solution, the concentration of the extract is not limited as long as the content of the dry solid content as a solute is within the above range.

  The external preparation for skin of the present invention can be prepared by blending into the bases of various forms according to a conventional method, using the above-mentioned Bregnum discolor extract as an anti-inflammatory agent. Further, by preparing the above-mentioned Bleknum discolor extract in combination with one or more other medicinal agents, an anti-inflammatory effect is further improved, or an external preparation for skin having other anti-inflammatory effects is also prepared. can do. Examples of other medicinal agents include, but are not limited to, whitening agents, UV protection agents, antibacterial agents, other anti-inflammatory agents, cell activators, active oxygen scavengers, and moisturizers. Absent.

  Examples of the whitening agent include ascorbic acid or a derivative thereof, arbutin, ellagic acid, linoleic acid, vitamin E and a derivative thereof, glycyrrhizic acid and a derivative thereof, tranexamic acid, placenta extract, chamomile extract, licorice extract, age Extract, Ougon extract, Seaweed extract, Kujin extract, Caiquet extract, Gokahi extract, Rice bran extract, Wheat germ extract, Saisin extract, Hawthorn extract, Sunpens extract, Shirayuri extract, Peonies extract Products, Sempukuka extract, soybean extract, tea extract, molasses extract, juniper extract, grape extract, hop extract, micaika extract, mokka extract, yukinoshita extract and the like.

  Examples of the UV protection agent include paramethoxycinnamate-2-ethylhexyl, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxybenzophenone-5 sodium sulfate, 4-t-butyl-4′- Examples thereof include methoxydibenzoylmethane, 2-phenyl-benzimidazole-5-sulfuric acid, titanium oxide, and zinc oxide.

  Examples of the antibacterial agent include benzoic acid, sodium benzoate, p-hydroxybenzoate ester, benzalkonium chloride, phenoxyethanol, isopropylmethylphenol, and the like.

  Other anti-inflammatory agents include, for example, sulfur and its derivatives, glycyrrhizic acid and its derivatives, glycyrrhetinic acid and its derivatives, Artea extract, Ashitaba extract, Arnica extract, Ginseng extract, nettle extract, and buckwheat extract , Hypericum extract, chamomile extract, goldfish extract, watercress extract, comfrey extract, salvia extract, sicon extract, perilla extract, birch extract, gentian extract and the like.

  Cell activators are used for the purpose of improving rough skin, such as caffeine, chicken crown extract, shell extract, shell extract, royal jelly, silk protein and its degradation products or derivatives thereof, lactoferrin or degradation products thereof. , Mucopolysaccharides such as chondroitin sulfate and hyaluronic acid or their salts, collagen, yeast extract, lactic acid bacteria extract, bifidobacteria extract, fermentation metabolic extract, ginkgo biloba extract, barley extract, assembly extract, lysium extract Products, carrot extract, rosemary extract, glycolic acid, citric acid, lactic acid, malic acid, tartaric acid, succinic acid and the like.

  The active oxygen scavenger has an action such as suppression of lipid peroxide production. For example, superoxide dismutase, mannitol, quercetin, catechin and derivatives thereof, rutin and derivatives thereof, button pi extract, yashajitsu extract, melissa extract , Lanahan fruit extract, retinol and its derivatives, vitamin A such as carotenoid, thiamine and its derivative, riboflavin and its derivative, pyridoxine and its derivative, vitamin B such as nicotinic acid and its derivative, tocopherol and its derivative, etc. Vitamin E, dibutylhydroxytoluene, butylhydroxyanisole, etc. are mentioned.

  Examples of the humectant include proteins such as elastin and keratin or derivatives thereof, hydrolysates and salts thereof, amino acids such as glycine, serine, aspartic acid, glutamic acid, arginine and theanine and derivatives thereof, sorbitol, erythritol, Trehalose, inositol, glucose, sucrose and derivatives thereof, dextrin and derivatives thereof, saccharides such as honey, D-panthenol and derivatives thereof, urea, phospholipid, ceramide, auren extract, ginger extract, diautum extract, sensyu extract Product, mallow extract, gypsophila extract, dokudami extract, hamamelis extract, bodaige extract, maronier extract, quince extract and the like.

  Moreover, arbitrary components other than the anti-inflammatory agent of this invention can be mix | blended with the skin external preparation of this invention. Examples of such components include, but are not limited to, physiologically active substances such as amino acids, lipids, sugars, hormones, enzymes, and nucleic acids. In addition, components that are usually used in the production of cosmetics, quasi-drugs, skin external preparations and the like, for example, water (purified water, hot spring water, deep water, etc.), oil agents, Surfactant, metal soap, gelling agent, powder, alcohol, water-soluble polymer, film forming agent, resin, inclusion compound, antibacterial agent, fragrance, deodorant, salt, pH adjuster, refreshing agent, Requires plant / animal / microbe-derived extracts, active oxygen scavengers, blood circulation promoters, astringents, antiseborrheic agents, moisturizers, chelating agents, keratolytic agents, enzymes, hormones, other vitamins, etc. Can be used accordingly.

  The external preparation for skin of the present invention has various forms such as powders such as powder and powder foundation; solids such as soap and lipstick; emulsions such as cream, emulsion and cream foundation; It is preferable that it is a cosmetic composition. However, it is not limited to these.

  Moreover, the anti-inflammatory agent of this invention is useful also as active ingredients, such as a foodstuff and a medicine other than the active ingredient of a skin external preparation.

EXAMPLES Hereinafter, the present invention will be described more specifically with reference to examples. However, the scope of the present invention is not limited to the following examples.
[Example 1: Preparation of Bleknum Discolor Extract]
After weaving the whole plant of the fernaceae Hryushida genus Brecnum discolor, pulverizing it, adding a water-ethyl alcohol mixture with an ethyl alcohol content of 30 vol%, and performing reflux extraction at about 90 ° C. for 2 hours, Suction filtered (filtrate 1). The residue was washed with a water-ethyl alcohol mixture having an ethyl alcohol content of 30 vol% and then suction filtered (filtrate 2). The filtrates 1 and 2 were combined and concentrated under reduced pressure to obtain a concentrated solution. Water and anhydrous ethyl alcohol were added in appropriate amounts to this concentrated liquid, the ethyl alcohol concentration was adjusted, and the mixture was allowed to stand for 3 days in a cool place, and the resulting sediment and precipitate were removed by suction filtration. This is further allowed to stand for 3 days in a cool place. Further, the generated oli and precipitates are removed by suction filtration, and at the same time, a water-ethyl alcohol mixture having an ethyl alcohol content of 50 vol% is added, and the Brecnum discolored extract is added. (Dry solid content concentration 3%) was prepared.
Further, a water-ethyl alcohol mixed solution having an ethyl alcohol content of 50 vol% was added to this extract, and test solution 1 (1% solution of the above Brecnum discolored extract, dry solid concentration was 3 × 10 ⁻² %) and test Liquids 2 (0.1% solution of the above Brecnum discolored extract, dry solid content concentration of 3 × 10 ⁻³ %) were prepared.

[Example 2: Anti-inflammatory test]
During the degranulation of rat basophil leukemia cells (RBL-2H3) induced by antigen stimulation, the amount of β-hexosaminidase released together with histamine etc. is measured and degranulated. As an indicator, the presence or absence of anti-inflammatory action of Bleknum discolor extract was confirmed. Specifically, the following tests were conducted.
RBL-2H3 cells purchased from ATCC (American Tissue Culture Collection) were cultured in Eagle's MEM medium (MEM, Sigma) containing 10% calf serum (FCS) at 37 ° C. in the presence of 5% CO ₂ . . Next, 2.0 × 10 ⁵ cells are seeded on a 24-well flat-bottom microplate (400 μL medium / well) for cell culture and cultured for 1 hour, and then rat monoclonal antibody DNP-IgE antibody (Sigma) is added to the culture solution. (Final concentration: 0.45 μg / mL) and cells were sensitized by culturing at 37 ° C. for 24 hours in the presence of 5% CO ₂ . The sensitized cells were then added to 500 μL of siraganian buffer (119 mmol / L NaCl, 5 mmol / L KCl, 0.4 mmol / L MgCl ₂ , 25 mmol / L piperazine-N, N′-bis (2-ethanesulfone). Acid) (PIPES), 40 mmol / L NaOH, pH 7.2) twice and 400 μL of 5.6 mmol / L glucose, 1 mmol / L CaCl ₂ , 0.1% BSA-containing Siraganian buffer added to 5% Pre-warmed for 10 minutes at 37 ° C. in the presence of CO ₂ . Next, 4 μL of each of the test solutions 1 and 2 prepared above was added, and 10 minutes later, the antigen (DNP-BSA) was added at a concentration shown in the following table and incubated for 30 minutes to stimulate the cells. After stopping the reaction by cooling with ice for 10 minutes, 50 μL of the supernatant was transferred to a 96-well flat bottom microplate, and 1 mmol / L p-nitrophenyl-N-acetyl-β- dissolved in 0.1 mol / L citrate buffer. After adding 50 μL of D-glucosaminide (PNAG) and mixing, the mixture was reacted at 37 ° C. for 1 hour. To the reaction solution, 200 μL of a reaction stop buffer (0.1 mmol / L NaCO ₃ / Na ₂ CO ₃ , pH 10.0) was added and mixed, and the absorbance was measured with a microplate reader (Model 550, Bio-Rad). (Measurement wavelength: 405 nm, reference wavelength: 655 nm). The β-hexosaminidase release rate was calculated from the obtained absorbance. For measurement of intracellular total β-hexosaminidase, a supernatant obtained by centrifuging a suspension of cells crushed by sonication in 0.5% Triton X-100 was used.

As a positive control, tranilast (positive control test solution 1: 0.5 mg / mL, positive control test solution 2: 0.2 mg / mL) used as an anti-inflammatory agent was used in the same manner as described above, and β-hex. The sosaminidase release rate was determined.
In addition, the β-hexosaminidase release rate in the sample to which each test solution was added was determined according to the following formula.

  Furthermore, from the calculated β-hexosaminidase release rate of each sample, the β-hexosaminidase release inhibition rate of each test solution was calculated according to the following formula.

  In the table below, the β-hexosaminidase release rate of the sample with each test solution added and the non-added sample (control), and the β-hexosaminidase release inhibition rate (in the table) for each test solution. Value in parentheses). In the table, β-hexosaminidase release inhibition rate is shown in parentheses. In addition, it shows that the degranulation is suppressed, so that the release rate of β-hexosaminidase is low, that is, the smaller the value, the higher the anti-inflammatory ability. On the other hand, the β-hexosaminidase release inhibition rate is an index of the degranulation inhibition rate, and the larger the value, the higher the degranulation inhibition ability, that is, the higher the anti-inflammatory ability.

  From the results shown in Table 1 above, it can be understood that the Bleknum discolor extract prepared in Example 1 exhibits β-hexosaminidase release inhibitory ability. In particular, it can be understood that Test Solution 1 exhibits a high inhibition rate of β-hexosaminidase release equivalent to that of tranilast which is practically used as an anti-inflammatory agent.

[Confirmation experiment on direct inhibitory effect of β-hexosaminidase activity]
The purpose of clarifying whether or not the inhibition of β-hexosaminidase release in Bleknum discolored extract is due to degranulation suppression or β-hexosaminidase direct inhibition, as revealed by the above results The following experiment was conducted.
Method:
The supernatant obtained by centrifuging cells disrupted by sonication in 0.5% Triton-X100 (PBS buffer) used for measurement of intracellular total β-hexosaminidase was used as an enzyme solution. To this enzyme solution, β-hexosaminidase activity was measured when the Bleknum discolor extract prepared in Example 1 was added at the concentrations shown in the following table. Specifically, 0.5 μL of Brecnum discolored extract having the concentration shown in the following table was added to 50 μL of the enzyme solution, and 1 mmol / L p-nitrophenyl-N— dissolved in 0.1 M citrate buffer. 50 μL of acetyl-β-D-glucosaminide (PNAG) was added and mixed, followed by reaction at 37 ° C. for 1 hour. To the reaction solution, 200 μL of a reaction stop buffer (0.1 mol / L NaHCO ₃ / Na ₂ CO ₃ , pH 10.0) was added and mixed, and the absorbance was measured with a microplate reader (Model 550, Bio-Rad). (Measurement wavelength: 405 nm, reference wavelength: 655 nm). The specific activity of β-hexosaminidase was calculated from the ratio of the measurement wavelengths minus the reference wavelength.

result:
The measurement results are shown in the following table.

From the results shown in the above table, the Bleknum discolor extract has a dry solid concentration of up to 0.03% (a high β-hexosaminidase release inhibitory concentration) and β-hexosaminidase itself. It can be understood that there is no inhibitory effect on.
Therefore, the Bleknum display extract does not directly inhibit β-hexosaminidase but inhibits release of β-hexosaminidase by suppressing degranulation of RBL-2H3 cells. It was revealed.

[Example 3: Preparation of cleansing cream]
A cleansing cream having the following composition was prepared by the following method.
(Ingredient) (%)
(1) Stearic acid 2.0
(2) Stearyl alcohol 3.0
(3) Lipophilic glyceryl monostearate 2.0
(4) Beeswax 1.5
(5) Vaseline 6.0
(6) Liquid paraffin 40.0
(7) Dimethylpolysiloxane (100CS) 0.5
(8) Sorbitan sesquioleate 1.0
(9) Preservative appropriate amount (10) Triethanolamine 1.0
(11) Propylene glycol 10.0
(12) Polyethylene glycol 20000 0.5
(13) Carboxyvinyl polymer 1% solution 5.0
(14) Purified water remaining amount (15) Brecnum Discolor Extract * 1 0.1
(16) Perfume appropriate amount * 1 Extract prepared in Example 1

(Manufacturing method)
A. Ingredients (1) to (9) are dissolved by heating and maintained at 70 ° C.
B. Ingredients (10) to (14) are dissolved by heating and maintained at 70 ° C.
C. A is added to B and emulsified.
D. After cooling C, components (15) and (16) were added and mixed to obtain a cleansing cream.

  The prepared cleansing cream had a good fit with makeup stains, clean makeup stains removed, moderate moisture and emollient on the skin, and was a non-sticky cleansing cream.

[Example 4: Preparation of face wash]
A face wash having the following composition was produced by the following method.
(Ingredient)%
(1) Lauric acid 5.0
(2) Myristic acid 18.5
(3) Stearic acid 6.0
(4) Glycerin 12.0
(5) Polyethylene glycol 1500 5.0
(6) Potassium hydroxide 6.5
(7) Purified water remaining amount (8) Palm oil fatty acid diethanolamide 5.0
(9) Palm oil fatty acid methyl taurine sodium 1.8
(10) Polyoxyethylene (7.5E.O.) lauryl ether 2.0
(11) Ethylene glycol distearate 1.0
(12) Hydroxypropyl methylcellulose 1% aqueous solution 5.0
(13) Bleknam Discolor Extract * 1 0.1
(14) Perfume appropriate amount * 1 Extract prepared in Example 1

(Manufacturing method)
A. Components (1) to (5) are dissolved by heating.
B. Components (6) and (7) are dissolved by heating.
C. Components (8) to (11) are dissolved by heating.
D. Add B to A and mix, then add C and mix.
E. After cooling D, components (12), (13) and (14) were added and mixed to obtain a face wash.

  The prepared face wash was rich and rich in foaming, had good stain removal, washes cleanly, and remained moist on the skin.

[Example 5: Preparation of lotion 1 (dissolving type)]
A lotion having the following composition was prepared by the following method.
(Ingredient)%
(1) Citric acid 0.05
(2) Sodium citrate 0.2
(3) Sodium pyrrolidonecarboxylate (50%) solution 0.5
(4) Bleknam Discolor Extract * 1 0.05
(5) Glycerin 3.0
(6) 1,3-butylene glycol 8.0
(7) Purified water remaining amount (8) Ethyl alcohol 10.0
(9) Perfume Appropriate amount (10) Preservative Appropriate amount (11) Polyoxyethylene monooleate (20E.O.)
Sorbitan 0.5
* 1 Extract prepared in Example 1

(Manufacturing method)
A. Components (1) to (7) are mixed and dissolved.
B. Components (8) to (11) are mixed and dissolved.
C. B was added to A and mixed to obtain a skin lotion.

  The prepared lotion is a lotion that has a fresh feeling of use, is excellent in moisture of the skin, and can be textured by applying to the skin every day to make the skin beautiful and elastic.

[Example 6: Preparation of lotion 2 (oil-solubilized type)]
A lotion having the following composition was prepared by the following method.
(Ingredient)%
(1) Meadow Home Oil 0.05
(2) Jojoba oil 0.05
(3) Perfume appropriate amount (4) preservative appropriate amount (5) polyoxyethylene monooleate (20E.O.)
Sorbitan 0.5
(6) Isostearic acid polyoxyethylene hydrogenated castor oil (50 EO) 1.0
(7) Ethyl alcohol 8.0
(8) Glycerin 5.0
(9) 1,3-butylene glycol 5.0
(10) Polyethylene glycol 1500 0.1
(11) Bleknam Discolor Extract * 1 0.2
(12) Purified water remaining amount * 1 Extract prepared in Example 1

(Manufacturing method)
A. Components (1) to (7) are mixed and dissolved.
B. Components (8) to (12) are mixed and dissolved.
C. A is added to B and mixed to obtain a skin lotion.

  The prepared lotion is a lotion that has a smooth feeling of use, is excellent in moisture, and can be applied to the skin every day to make the skin smooth and beautiful. .

[Example 7: Preparation of lotion 3 (emulsification type)]
A lotion having the following composition was prepared by the following method.
(Ingredient)%
(1) Glyceryl tri-2-ethylhexanoate 0.08
(2) Squalane 0.02
(3) Sorbitan sesquioleate 0.05
(4) Polyoxyethylene monooleate (20E.O.)
Sorbitan 0.05
(5) Polyoxyethylene (8E.O.) alkyl (12-15)
Ether phosphoric acid 0.1
(6) Preservative appropriate amount (7) perfume appropriate amount (8) ethyl alcohol 8.0
(9) Dipropylene glycol 8.0
(10) Glycerin 4.0
(11) Bleknam Discolor Extract * 1 0.1
(12) Purified water remaining amount * 1 Extract prepared in Example 1

(Manufacturing method)
A. Components (1) to (8) are mixed and dissolved.
B. Components (9) to (12) are mixed and dissolved.
C. A is added to B and emulsified to obtain a skin lotion.

  The prepared lotion has a fresh and refreshing feeling of use, is excellent in moisturizing the skin, and can be applied to the skin every day to make the texture smooth and glossy. Met.

[Example 8: Preparation of emulsion]
An emulsion having the following composition was prepared by the following method.
(Ingredient)%
(1) Stearic acid 1.0
(2) Cetanol 0.5
(3) Lipophilic glyceryl monostearate 0.5
(4) Liquid paraffin 2.0
(5) Squalane 3.0
(6) Jojoba oil 3.0
(7) Cetyl palmitate 0.2
(8) Preservative appropriate amount (9) Sorbitan monostearate 0.3
(10) Polyoxyethylene monooleate (20E.O.)
Sorbitan 0.5
(11) Triethanolamine 0.5
(12) 1,3-butylene glycol 15.0
(13) Glycerin 3.0
(14) Polyethylene glycol 6000 0.5
(15) Purified water Remaining amount (16) Carboxyvinyl polymer 1% solution 8.0
(17) Bleknam Discolor Extract * 1 0.2
(18) Fragrance Appropriate amount * 1 Extract prepared in Example 1

(Manufacturing method)
A. Ingredients (1) to (10) are dissolved by heating and maintained at 70 ° C.
B. Ingredients (11) to (15) are dissolved by heating and maintained at 70 ° C.
C. B is added to A to emulsify, and component (16) is further added and mixed.
D. C is cooled, and components (17) and (18) are added and mixed to obtain an emulsion.

  The prepared emulsion has a fresh and smooth feeling of use, is excellent in moisture and emollient, and is applied to the skin every day to make the texture smooth and glossy. Met.

Example 9: Preparation of cream
The following compositional claims were prepared in the following manner.
(Ingredient)%
(1) Stearic acid 2.5
(2) Cetanol 2.5
(3) Lipophilic glyceryl monostearate 2.0
(4) Vaseline 2.0
(5) Dipentaerythritol fatty acid ester * 1 2.0
(6) Isotridecyl myristate 5.0
(7) Liquid paraffin 8.0
(8) Squalane 5.0
(9) Beeswax 1.0
(10) Cetyl palmitate 2.0
(11) Sorbitan sesquioleate 0.5
(12) Polyoxyethylene monooleate (20E.O.)
Sorbitan 1.5
(13) Preservative appropriate amount (14) Triethanolamine 1.2
(15) 1,3-butylene glycol 8.0
(16) Glycerin 2.0
(17) Polyethylene glycol 20000 0.5
(18) Purified water remaining amount (19) 1% aqueous solution of carboxyvinyl polymer 5.0
(20) Bleknam Discolor Extract * 2 1.0
(21) Fragrance appropriate amount * 1: Cosmol 168AR (Nisshin Oillio Group)
* 2 Extract prepared in Example 1

(Manufacturing method)
A. Ingredients (1) to (13) are dissolved by heating and maintained at 70 ° C.
B. Ingredients (14) to (18) are dissolved by heating and maintained at 70 ° C.
C. B is added to A to emulsify, and component (19) is further added and mixed.
D. C is cooled, and components (20) and (21) are added and mixed to obtain an emulsion.

  The prepared cream had a rich and smooth feeling of use, was excellent in emollient skin, and when applied to the skin every day, it was smooth and glossy, and it was a cream that could be made into beautiful skin with elasticity.

[Example 10: Preparation of serum (solubilized type)]
A serum having the following composition was prepared by the following method.
(Ingredient)%
(1) Glyceryl tri-2-ethylhexanoate 0.1
(2) Meadow Home Oil 0.05
(3) Jojoba oil 0.05
(4) Preservative appropriate amount (5) perfume appropriate amount (6) polyoxyethylene monooleate (20E.O.)
Sorbitan 0.5
(7) Polyoxyethylene hydrogenated isostearate castor oil (50 EO) 1.5
(8) Ethyl alcohol 5.0
(9) Glycerin 4.0
(10) Dipropylene glycol 8.0
(11) 1,3-butylene glycol 8.0
(12) Sodium lactate 0.5
(13) Sodium pyrrolidonecarboxylate (50%) solution 0.5
(14) Hydroxyethyl cellulose 0.08
(15) Sodium alginate 0.05
(16) Bleknam Discolor Extract * 1 0.1
(17) Remaining amount of purified water * 1 Extract prepared in Example 1

(Manufacturing method)
A. Components (1) to (8) are mixed and dissolved.
B. Components (9) to (17) are mixed and dissolved.
C. A was added to B and mixed to obtain a serum.

  The prepared essence has a fresh, smooth and mild feeling of use, is excellent in moisture and emollient skin, and is applied to the skin every day to make it smooth and glossy. It was a serum that could be used.

[Example 11: Preparation of pack (peel-off type)]
A pack having the following composition was prepared by the following method.
(Ingredient)%
(1) Polyvinyl alcohol 12.0
(2) Methylcellulose 0.1
(3) Glycerin 3.0
(4) 1,3-butylene glycol 5.0
(5) Purified water remaining amount (6) perfume appropriate amount (7) preservative appropriate amount (8) glyceryl tri-2-ethylhexanoate 0.1
(9) Polyoxyethylene monooleate (20E.O.)
Sorbitan 1.0
(10) Ethyl alcohol 13.0
(11) Bleknam Discolor Extract * 1 0.1
* 1 Extract prepared in Example 1

(Manufacturing method)
A. Components (1) to (5) are dissolved by heating.
B. Components (6) to (10) are mixed and dissolved.
C. After cooling A, B and (11) were added and mixed to obtain a pack.

  The prepared pack was a pack that stretched well, imparted moderate tension to the skin, had no stickiness on the skin after peeling off the pack, and had a high moisture and weight.

[Example 12: Preparation of massage cream]
A massage cream having the following composition was prepared by the following method.
(Ingredient)%
(1) Stearic acid 2.0
(2) Stearyl alcohol 2.5
(3) Lipophilic glyceryl monostearate 2.0
(4) Sorbitan sesquioleate 1.0
(5) Cetyl palmitate 1.0
(6) Dipentaerythritol fatty acid ester * 1 4.0
(7) Vaseline 20.0
(8) Liquid paraffin 28.0
(9) Methyl polysiloxane (100CS) 0.5
(10) Sodium hydroxide 0.1
(11) Dipropylene glycol 7.0
(12) 1% solution of carboxyvinyl polymer 5.0
(13) Purified water remaining amount (14) Brecnum Discolored Extract * 2 0.2
(15) Fragrance appropriate amount * 1: Cosmol 168AR (Nisshin Oillio Group)
* 2: Extract prepared in Example 1

(Manufacturing method)
A. Ingredients (1) to (9) are dissolved by heating and maintained at 70 ° C.
B. Components (10) to (13) are dissolved by heating and maintained at 70 ° C.
C. A is added to B and emulsified.
D. After cooling C, components (14) and (15) were added and mixed to obtain a massage cream.

  The prepared massage cream had a smooth and rich feeling of use, had an excellent massage effect, and was highly effective in preventing sagging of the skin and the decrease in elasticity.

[Example 13: Preparation of cream foundation (W / O type)]
A cream foundation having the following composition was prepared by the following method.
(Ingredient)%
(1) Sericite 8.0
(2) Titanium oxide 10.0
(3) Bengala 1.0
(4) Yellow iron oxide 2.2
(5) Mica titanium 2.0
(6) Black iron oxide 0.1
(7) Organic metamorphic bentonite * 1 0.5
(8) Long chain alkyl-containing polyoxyalkylene modified organopolysiloxane * 2 2.0
(9) Polyoxyalkylene-modified organopolysiloxane * 3 2.0
(10) Decamethylcyclopentasiloxane 12.0
(11) Octamethylcyclotetrasiloxane 10.0
(12) Trimethylsiloxysilicic acid silicone solution * 4 3.0
(13) Glyceryl tri-2-ethylhexanoate 5.0
(14) 1,3-butylene glycol 5.0
(15) Diglycerin 2.0
(16) Glycerin 2.0
(17) Xanthan gum 0.2
(18) Sodium chloride 0.2
(19) Purified water remaining amount (20) Brecnum discolored extract * 5 0.1
(21) Perfume appropriate amount * 1: Benton 38 (manufactured by NL Endowry)
* 2: Avil EM-90 (Gold Schmidt)
* 3: KF-6017 (manufactured by Shin-Etsu Chemical Co., Ltd.)
* 4: KF-7312J (manufactured by Shin-Etsu Chemical Co., Ltd.)
* 5: Extract prepared in Example 1

(Manufacturing method)
A: Components (8) to (13) are mixed.
B: Components (14) to (19) are mixed.
C: Components (1) to (7) are added to A and mixed and dispersed.
D: Components (20) and (21) were added to C to obtain a cream foundation (W / O type).

  The prepared cream foundation has a smooth, non-sticky feel, excellent adhesion to the skin, and a beautiful finish.When applied to the skin every day, it gives an emollient feel and is also elastic. It was a cream foundation that could make some beautiful skin.

  ADVANTAGE OF THE INVENTION According to this invention, the safe anti-inflammatory agent derived from a plant and the anti-inflammatory skin external preparation can be provided. Since the anti-inflammatory agent of the present invention has the ability to suppress degranulation accompanied by the release of β-hexosaminidase, it can suppress or improve inflammation caused by pharmacologically active substances such as histamine contained in the released granules. Useful.

Claims (5)

An anti-inflammatory agent comprising, as an active ingredient, an extract of Blechnaceae (Blechnumae), Blechnum discolor (Blechnum discolor). The anti-inflammatory agent according to claim 1, which has an ability to inhibit β-hexosaminidase release. The anti-inflammatory agent according to claim 1 or 2, which has an ability to suppress degranulation accompanied by release of β-hexosaminidase. An anti-inflammatory skin external preparation containing an extract of the genus Blencaceae (Blechnumae), Blechnum discolor (Blechnum discolor). The anti-inflammatory skin external preparation which contains the anti-inflammatory agent of any one of Claims 1-3 as an active ingredient.